2. Academic Validation
  3. BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance

BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance

  • Cell Rep. 2018 Sep 25;24(13):3513-3527.e7. doi: 10.1016/j.celrep.2018.08.086.
Joseph Nacson 1,  John J Krais 2,  Andrea J Bernhardy 2,  Emma Clausen 2,  Wanjuan Feng 3,  Yifan Wang 2,  Emmanuelle Nicolas 4,  Kathy Q Cai 5,  Rossella Tricarico 6,  Xiang Hua 7,  Daniela DiMarcantonio 7,  Esteban Martinez 7,  Dali Zong 8,  Elizabeth A Handorf 9,  Alfonso Bellacosa 6,  Joseph R Testa 10,  Andre Nussenzweig 8,  Gaorav P Gupta 3,  Stephen M Sykes 7,  Neil Johnson 11
Affiliations

Affiliations

  • 1 Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA; Temple University, Lewis Katz School of Medicine, Philadelphia, PA 19140, USA.
  • 2 Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
  • 3 Department of Radiation Oncology, UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
  • 4 Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA; Genomics Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
  • 5 Histopathology Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
  • 6 Cancer Epigenetics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
  • 7 Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
  • 8 Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
  • 9 Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
  • 10 Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
  • 11 Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. Electronic address: neil.johnson@fccc.edu.
PMID: 30257212 DOI: 10.1016/j.celrep.2018.08.086
Abstract

BRCA1 functions in homologous recombination (HR) both up- and downstream of DNA end resection. However, in cells with 53BP1 gene knockout (KO), BRCA1 is dispensable for the initiation of resection, but whether BRCA1 activity is entirely redundant after end resection is unclear. Here, we found that 53bp1 KO rescued the embryonic viability of a Brca1ΔC/ΔC mouse model that harbors a stop codon in the coiled-coil domain. However, Brca1ΔC/ΔC;53bp1-/- mice were susceptible to tumor formation, lacked RAD51 foci, and were sensitive to PARP Inhibitor (PARPi) treatment, indicative of suboptimal HR. Furthermore, BRCA1 mutant Cancer cell lines were dependent on truncated BRCA1 proteins that retained the ability to interact with PALB2 for 53BP1 KO induced RAD51 foci and PARPi resistance. Our data suggest that the overall efficiency of 53BP1 loss of function induced HR may be BRCA1 mutation dependent. In the setting of 53BP1 KO, hypomorphic BRCA1 proteins are active downstream of end resection, promoting RAD51 loading and PARPi resistance.

Keywords

53BP1; BRCA1; PARP inhibitors; homologous recombination; resistance.

Figures
Products